Leading health and well-being company Humana Inc. announced that, for the third consecutive year and the fourth time overall, its statewide Humana HMO Medicare Advantage plan in Tennessee has achieved the highest possible 5-star rating from the Centers for Medicare & Medicaid Services.
Humana Tennessee Medicare Advantage HMO Plan Achieves Highest Quality Rating for 2024 Read More »
Immunic, Inc. announced the presentation of data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, in patients with celiac disease in a moderated poster session at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.
Ankyra Therapeutics presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.
Aulos Bioscienc presented new pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007, the first human monoclonal antibody designed using artificial intelligence to be tested in a clinical trial.
Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.
Opinion: Interest in RNA Editing Accelerates as Therapies Approach the Clinic Read More »
The FDA is gearing up for six decisions in the next two weeks, two of which involve highly anticipated medicines for rare diseases.
FDA Action Alert: Merck, Ardelyx, BioMarin and More Read More »
Recomendaciones del Royal College of Physicians del Reino Unido para adultos de atención primaria y secundaria.
Abordaje en el ámbito médico y quirúrgico | Fibromialgia Read More »
About 42% of Medicare Advantage plans that offer prescription drug coverage in 2024 earned four or more stars, compared with just over half this year.
Share of MA, Part D plans earning top star ratings drops in 2024 Read More »
The European Commission ordered the gene sequencing company to support Grail with two-and-a-half years of funding if it pursues a spinoff.
Illumina details EC timeline, funding requirements for Grail divestment Read More »
